Skip to main content

Advertisement

SpringerLink
Log in

Advances in Adjuvant Therapy of Gastrointestinal Stromal Tumors

  • Sarcomas (SR Patel, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The Gastrointestinal Stromal Tumor (GIST) is the most common sarcoma of the gastrointestinal tract. Major prognostic indices in the evaluation and management of GIST include the size, location and tumor mitotic rate. The discovery of the mutation in the tyrosine kinase receptor c-KIT (CD117) revolutionized the treatment of GIST in the early twenty-first century. Since the first case report of the success of the tyrosine kinase inhibitor (TKI) imatinib, in the treatment of a female patient with metastatic GIST, the paradigm of treatment of this tumor has evolved tremendously. The initial use in metastatic GISTs has progressed to use of the TKI in both the adjuvant and neoadjuvant settings. It is now standard of care for patients with complete resection of primary localized GIST, with high risk of recurrence, to have at least one year of adjuvant imatinib. Recent SSGVXIII study shows that patients benefit from extended duration of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Winer JH, Raut CP. Management of recurrent gastrointestinal stromal tumors. J Surg Oncol. 2011;104:915–20.

    Article  PubMed  CAS  Google Scholar 

  2. Li J, Gong JF, Wu AW, Shen L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol. 2011;37:319–24.

    Article  PubMed  CAS  Google Scholar 

  3. Reynoso D, Trent JC. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Curr Opin Oncol. 2010;22:330–5.

    Article  PubMed  CAS  Google Scholar 

  4. Pisters PW, Patel SR. Gastrointestinal stromal tumors: current management. J Surg Oncol. 2010;102:530–8.

    Article  PubMed  Google Scholar 

  5. Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011;129:2533–42.

    Article  PubMed  CAS  Google Scholar 

  6. Sanford M, Scott LJ. Imatinib: as adjuvant therapy for gastrointestinal stromal tumour. Drugs. 2010;70:1963–72.

    Article  PubMed  CAS  Google Scholar 

  7. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466–77.

    Article  PubMed  CAS  Google Scholar 

  8. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608–15.

    Article  PubMed  Google Scholar 

  9. D'Adamo D. Advances in the treatment of gastrointestinal stromal tumor. Adv Ther. 2009;26:826–37.

    Article  PubMed  Google Scholar 

  10. Patrikidou A, Domont J, Cioffi A, Le Cesne A. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol. 2011;12:21–31.

    Article  PubMed  Google Scholar 

  11. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.

    Article  PubMed  CAS  Google Scholar 

  12. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature. 1995;373:347–9.

    Article  PubMed  CAS  Google Scholar 

  13. Maeda H, Yamagata A, Nishikawa S, Yoshinaga K, Kobayashi S, Nishi K. Requirement of c-kit for development of intestinal pacemaker system. Development. 1992;116:369–75.

    PubMed  CAS  Google Scholar 

  14. Ganjoo KN, Patel S. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Drugs. 2011;71:321–30.

    Article  PubMed  Google Scholar 

  15. Chaudhry UI, DeMatteo RP. Management of resectable gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009;23(1):79–96.

    Google Scholar 

  16. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003;65:187–97.

    Article  PubMed  Google Scholar 

  17. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network : JNCCN 2010;8 S-1-S-41.

  18. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47:853–9.

    Article  PubMed  CAS  Google Scholar 

  19. Duffaud F, Salas S, Huynh T. Recent advances in the management of gastrointestinal stromal tumors. F1000 medicine reports 2010;2:36.

  20. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol. 2011;223:251–61.

    Article  PubMed  CAS  Google Scholar 

  21. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5years later. Cancer. 2005;104:1781–8.

    Article  PubMed  Google Scholar 

  22. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10:3282–90.

    Article  PubMed  CAS  Google Scholar 

  23. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.

    Article  PubMed  CAS  Google Scholar 

  24. Joensuu H. Predicting recurrence-free survival after surgery for GIST. The lancet oncology. 2009;10:1025.

    Article  PubMed  Google Scholar 

  25. Eisenberg BL, Smith KD. Adjuvant and neoadjuvant therapy for primary GIST. Cancer Chemother Pharmacol. 2011;67 Suppl 1:S3–8.

    Article  PubMed  Google Scholar 

  26. Bilimoria KY, Wayne JD, Merkow RP, et al. Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. Ann Surg Oncol 2012;19:184–191.

    Google Scholar 

  27. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.

    Article  PubMed  CAS  Google Scholar 

  28. Learn PA, Sicklick JK, DeMatteo RP. Randomized clinical trials in gastrointestinal stromal tumors. Surg Oncol Clin N Am. 2010;19:101–13.

    Article  PubMed  Google Scholar 

  29. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev. 2011;37:291–9.

    Article  Google Scholar 

  30. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.

    Article  PubMed  CAS  Google Scholar 

  31. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer. 2005;41:1751–7.

    Article  PubMed  CAS  Google Scholar 

  32. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37:75–88.

    Article  PubMed  CAS  Google Scholar 

  33. • Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104. The randomized phase III trial comparing imatinib 400mg daily for 1 year to placebo showing an improvement in overall survival.

    Article  PubMed  CAS  Google Scholar 

  34. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist. 2010;15:300–7.

    Article  PubMed  CAS  Google Scholar 

  35. • Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 2011;29 (suppl; abstr LBA1). The randomized, phase III trial comapring imatinib for 12months to imatinib 36months, showing an improvement of overall survival

  36. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13.

    Article  PubMed  CAS  Google Scholar 

  37. Gronchi A, Judson I, Nishida T, et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer. 2009;45:1103–6.

    Article  PubMed  Google Scholar 

  38. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–90.

    Article  PubMed  CAS  Google Scholar 

  39. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.

    Article  PubMed  CAS  Google Scholar 

  40. Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117:4633–41.

    Google Scholar 

  41. Kim EJ, Zalupski MM. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol. 2011;104:901–6.

    Article  PubMed  CAS  Google Scholar 

  42. Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer. 2011;104:1686–90.

    Article  PubMed  CAS  Google Scholar 

  43. Schoffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010;21:1990–8.

    Article  PubMed  CAS  Google Scholar 

  44. Dematteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate follwoing complete resection on localized, primary gastrointestinal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z7900 American Society of Clinical Oncology (ASCO) 2008 Gastrointestinal Cancers Symphosium 2008 – Abstract No. 8.

  45. Kang B, Lee J, Ryu M, et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol 2009;27 (suppl; abstr LBA1).

  46. Health USNIo. ClinicalTrials.gov. 2012.

Download references

Disclosure

K. Adekola: none; M. Agulnik: honoraria from and speakers’ bureaus for Novartis.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, 676 North St. Clair Street, Suite 850, Chicago, IL, 60611, USA

    K. Adekola & M. Agulnik

Authors
  1. K. Adekola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Agulnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Agulnik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adekola, K., Agulnik, M. Advances in Adjuvant Therapy of Gastrointestinal Stromal Tumors. Curr Oncol Rep 14, 327–332 (2012). https://doi.org/10.1007/s11912-012-0241-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0241-0

Keywords

Search

Navigation